MCL Literature Feed
41 papers on mantle cell lymphoma from PubMed. Updated daily.
The frontline, chemotherapy-free triplet of acalabrutinib, venetoclax, and rituximab achieved 100% ORR and high MRD negativity, establishing a potent, time-limited option despite significant COVID-19 toxicity.
Seven-year follow-up of venetoclax-ibrutinib in relapsed/refractory MCL shows durable responses (30% PFS) and demonstrates feasibility of MRD-guided treatment-free remission, supporting a long-term chemotherapy-free strategy.
This study analyzes molecular responses in exceptional responders to the BTKi tirabrutinib, aiming to identify biomarkers for deep, durable remissions in relapsed/refractory mantle cell lymphoma.
This review summarizes how molecular profiling (e.g., TP53) and MRD are reshaping MCL therapy by integrating novel agents into frontline care, personalizing treatment, and improving high-risk patient outcomes.
For transplant-eligible MCL, substituting rituximab with obinutuzumab in chemo-immunotherapy induction and maintenance significantly improved MRD negativity, 5-year progression-free survival (83% vs 67%), and overall survival.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
A transplant-sparing frontline regimen of lenalidomide-R-CHOP/R-HiDAC showed favorable outcomes in TP53 wild-type high-risk MCL, but not TP53-mutated MCL, reinforcing the prognostic power of sequential MRD monitoring.
This retrospective analysis shows peripheral blood Ig-HTS MRD testing (clonoSEQ) effectively predicts relapse earlier than imaging in MCL patients, supporting its use as a surveillance tool post-frontline therapy.
Combining time-limited ibrutinib with CTL019 CAR-T in relapsed/refractory MCL achieved an 80% CR rate with manageable toxicity, showing efficacy even in BTKi-pretreated and TP53-mutated patients.
In elderly MCL, rituximab maintenance benefits even MRD-negative patients post-induction, arguing against de-escalation and identifying MRD-positivity as a high-risk feature needing better consolidation.
Ibrutinib plus venetoclax shows high efficacy (83% CR) and deep MRD negativity with good tolerability in Japanese patients with relapsed/refractory MCL, supporting its use in this population.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
An MRD-driven, finite-duration venetoclax-lenalidomide-rituximab regimen is effective in relapsed/refractory MCL, even post-BTKi, allowing nearly half of patients to stop therapy and maintain durable molecular remissions.